Готові списки джерел за темами / Uveitis treatment

Добірка наукової літератури з теми "Uveitis treatment"

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Uveitis treatment".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Uveitis treatment"

Du, Lin, Yolanda Wong Ying Yip, Him Kwan Ng, Bo Man Ho, Jing-Na He, Sun On Chan, Chi Pui Pang, and Wai Kit Chu. "Ruxolitinib Alleviates Uveitis Caused by Salmonella typhimurium Endotoxin." Microorganisms 9, no. 7 (July 11, 2021): 1481. http://dx.doi.org/10.3390/microorganisms9071481.

Повний текст джерела

Анотація:

Uveitis is characterized by inflammatory lesions of intraocular structures. It is one of the important manifestations in patients with Reiter’s syndrome, an inflammatory arthritis, which is caused by enteric infection with bacteria, including Salmonella typhimurium. Corticosteroids remain the most frequently used therapies against uveitis associating with inflammatory arthritis. However, the long-term administration of steroids results in many side effects, and some uveitis patients do not respond to steroid treatment. Non-steroidal treatments are needed for uveitis patients. Our previous study found that Janus kinase (JAK) 1/2 inhibitor, ruxolitinib could suppress the expression of proinflammatory mediators in the ciliary body and iris. However, the impacts of ruxolitinib on ophthalmic features in uveitic eyes are still unknown. In this study, Salmonella typhimurium endotoxin-induced uveitis (EIU) was induced in Sprague Dawley rats by the injection of lipopolysaccharide (LPS). Compared with LPS-induced rats treated with water, ruxolitinib significantly attenuated the clinical manifestations, infiltrating cells and protein exudation in the aqueous humor, and retina–choroid thickening. Amplitudes of b-wave in both scotopic and photopic electroretinogram (ERG), and the amplitude of a-wave in scotopic ERG in EIU animals were alleviated by ruxolitinib. Collectively, we propose ruxolitinib could attenuate endotoxin-induced uveitis and rescue visual functions in rats by inhibiting the JAK2-STAT3 pathway.

Стилі APA, Harvard, Vancouver, ISO та ін.

Al-Dhibi, Hassan, Issam H. Hamade, Ali Al-Halafi, Maan Barry, Charbel Bou Chacra, Vishali Gupta, and Khalid F. Tabbara. "The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema." Journal of Ophthalmology 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/729465.

Повний текст джерела

Анотація:

Background/Aims.To assess the effect of intravitreal bevacizumab injection (IVBI) for the treatment of macular edema due to infectious and noninfectious uveitides.Design.Retrospective interventional case series.Methods.A chart review was performed on all the patients who were diagnosed with uveitic macular edema (UME) and received 1.25 mg of IVBI at two referral centers in Riyadh, Saudi Arabia. All included patients had their visual acuity and macular thickness analyzed at baseline and at 1 and 3 months following IVBI and any sign of reactivation was noted.Results.The mean age of patients was41±16years with a mean followup of4±1months. Ten patients had idiopathic intermediate uveitis, 9 patients had Behcet’s disease, 10 had idiopathic panuveitis, and twelve patients had presumed ocular tuberculosis uveitis. Following IVBI, the mean LogMAR visual acuity improved from0.8±0.8at baseline to0.4±0.5at 1 month and0.3±0.5at 3 months (P<0.002, at 3 months). The mean macular thickness was430±132 μm at baseline. Following IVBI macular thickness improved to286±93 μm at 1 month and to265±88 μm at 3 months of followup (P<0.001, at 3 months).Conclusion.Bevacizumab was effective in the management of UME associated with both infectious and noninfectious uveitides. Intravitreal bevacizumab induced remission of UME with infectious uveitis and had no immunosuppressive effect against infectious agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

Géhl, Zsuzsanna, Zsuzsanna Szepessy та Zoltán Zsolt Nagy. "A TNFα-gátló szemészeti alkalmazása: adalimumabkezelés uveitisben". Orvosi Hetilap 162, № 34 (22 серпня 2021): 1370–75. http://dx.doi.org/10.1556/650.2021.32188.

Повний текст джерела

Анотація:

Összefoglaló. Bevezetés: Az adalimumab egy TNFα-gátló monoklonális antitest; számos indikációja közül a nem fertőzéses eredetű intermedier, posterior és panuveitisek kezelésében is általánosan alkalmazható készítmény. Célkitűzés: A felnőttkori nem fertőzéses eredetű uveitis miatt adalimumabkezelést kapó betegekkel szerzett tapasztalataink összefoglalása. Betegek és módszerek: Retrospektív esetsorozatban vizsgáljuk a budapesti Uveitis Centrumban (a Semmelweis Egyetem Szemészeti Klinikájának Uveitis Ambulanciáján) 2018 és 2020 között adalimumabbal kezelt felnőtt, nem fertőzéses eredetű uveitises eseteinket. Eredmények: 13 beteget mutatunk be (8 nő, 5 férfi), átlagéletkor 45 (26–80) év. Az adalimumabot 12 beteg Humira, 1 beteg Amgevita készítmény formájában kapja. Az uveitis eredete 2 esetben ’birdshot’ chorioretinitis, 2 esetben Behçet-kór, 1 esetben sarcoidosis, 3 esetben retinalis vasculitis, 1 esetben Vogt–Koyanagi–Harada-betegség volt, és 4 esetben idiopathiás eredetűnek bizonyult. Az adalimumabkezelést 7 betegnél kellett elhagyni, elsősorban terápiás elégtelenség miatt, míg 6 betegnél jelenleg is eredményesen folyik a kezelés. Következtetés: Tapasztalataink alapján az adalimumab biztonságos, kevés mellékhatással bíró, hatékony kezelés számos uveitisformában önmagában adva vagy kis dózisú szteroiddal kiegészítve. Korábbi terápiákra (szteroid, immunszuppresszió) rezisztens esetekben is alkalmazható. A szemészetben a szisztémás biológiai terápia, az adalimumab bevezetése az uveitises betegek kezelésében a látóélesség megőrzése szempontjából sorsdöntő jelentőségű. Orv Hetil. 2021; 162(34): 1370–1375. Summary. Introduction: Adalimumab is a monoclonal antibody that inhibits TNFα and among other indications it can be a systemic treatment in the non-infectious intermediate, posterior and panuveitis. Objective: To summarize our experience in patients receiving adalimumab for adult non-infectious uveitis. Patients and methods: We investigate our adult cases of non-infectious uveitis treated with adalimumab between 2018 and 2020 in a retrospective case series at the Uveitis Center in Budapest (Semmelweis University, Department of Ophthalmology, Uveitis Department). Results: We present 13 patients (8 females, 5 males) with a mean age of 45 (26–80) years. Adalimumab is given to 12 patients as Humira and 1 patient as Amgevita. The etiology of uveitis was in 2 cases birdshot chorioretinitis, 2 Behçet’s disease, 1 sarcoidosis, 3 retinal vasculitis, 1 Vogt–Koyanagi–Harada disease, and 4 of idiopathic origin. Adalimumab treatment had to be discontinued in 7 cases, mainly due to therapeutic insufficiency, while in 6 cases we are still successfully treating patients. Conclusion: According to our experience, adalimumab is a safe and effective treatment, with minimal side effect in many forms of uveitis alone, or in combination with a low-dose steroid. It can also be used in cases where traditional immunosuppressive therapies are ineffective. In ophthalmology, systemic biologic therapy, availability of adalimumab in the treatment of uveitis is crucial for maintaining visual acuity at affected patients. Orv Hetil. 2021; 162(34): 1370–1375.

Стилі APA, Harvard, Vancouver, ISO та ін.

Tallouzi, Mohammad O., David J. Moore, Nicholas Bucknall, Philip I. Murray, Melanie J. Calvert, Alastair K. Denniston, and Jonathan M. Mathers. "Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study." BMJ Open Ophthalmology 5, no. 1 (July 2020): e000481. http://dx.doi.org/10.1136/bmjophth-2020-000481.

Повний текст джерела

Анотація:

ObjectiveUveitis, a group of disorders characterised by intraocular inflammation, causes 10%–15% of total blindness in the developed world. The most sight-threatening forms of non-infectious uveitis are those affecting the posterior segment of the eye, collectively known as posterior segment-involving uveitis (PSIU). Numerous different clinical outcomes have been used in trials evaluating treatments for PSIU, but these may not represent patients’ and carers’ concerns. Therefore, the aims of this study were to understand the impact of PSIU on adult patients’ and carers’ lives and to explore what outcomes of treatment are important to them.Methods and AnalysisFour focus group discussions were undertaken to understand the perspectives of adult patients (=18) and carers (10) with PSIU. Participants were grouped according to whether or not their uveitis was complicated by the sight-threatening condition uveitic macular oedema. Discussions were audio-recorded, transcribed and analysed using the framework analytical approach. Outcomes were identified and grouped into outcome domains.ResultsEleven core domains were identified as important to patients and carers undergoing treatment for PSIU, comprising (1) visual function, (2) symptoms, (3) functional ability, (4) impact on relationships, (5) financial impact, (6) psychological morbidity and emotional well-being, (7) psychosocial adjustment to uveitis, (8) doctor/patient/interprofessional relationships and access to healthcare, (9) treatment burden, (10) treatment side effects, and (11) disease control.ConclusionThe domains identified represent patients’ and carers’ experience and perspectives and can be used to reflect on outcomes assessed in PSIU. They will directly inform the development of a core outcome set for PSIU clinical trials.

Стилі APA, Harvard, Vancouver, ISO та ін.

BenEzra, David. "IMMUNOSUPPRESSIVE TREATMENT OF UVEITIS." International Ophthalmology Clinics 30, no. 4 (1990): 309–13. http://dx.doi.org/10.1097/00004397-199030040-00022.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Dinning, William J. "Medical treatment of uveitis." Current Opinion in Ophthalmology 1, no. 4 (August 1990): 402–4. http://dx.doi.org/10.1097/00055735-199001040-00012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Deutman, August F. "Surgical treatment of uveitis." Current Opinion in Ophthalmology 1, no. 4 (August 1990): 405–7. http://dx.doi.org/10.1097/00055735-199001040-00013.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Dinning, William J. "Medical treatment of uveitis." Current Opinion in Ophthalmology 1, no. 4 (August 1990): 402–4. http://dx.doi.org/10.1097/00055735-199008000-00012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Deutman, August F. "Surgical treatment of uveitis." Current Opinion in Ophthalmology 1, no. 4 (August 1990): 405–7. http://dx.doi.org/10.1097/00055735-199008000-00013.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Harrington, Monica. "Advances in uveitis treatment." Lab Animal 36, no. 10 (November 2007): 8. http://dx.doi.org/10.1038/laban1107-8b.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Uveitis treatment"

Shirodkar, A. "Retinal vascular involvement in uveitis and new treatment options." Thesis, University College London (University of London), 2013. http://discovery.ucl.ac.uk/1348740/.

Повний текст джерела

Анотація:

The retinal blood vessels can become occluded due to both inflammation and thromboembolic diseases, and the main aim of this thesis is to examine the features of retinal vein occlusion (RVO) in patients with co-existing ocular inflammation to determine risk factors for the development of RVO, risk factors predictive of a poor visual outcome in uveitis, the prevalence of anti phospholipid antibody-based disease and the role of antiphospholipid antibody (aPL) testing. In this thesis, I also explore the efficacy of new treatments for retinal vein occlusion, particularly the Ozurdex intravitreal dexamethasone implant, which can also be used to treat uveitis and uveitis macular oedema. Demographic and clinical variables were extracted from the medical notes of three separate sample groups of patients attending Moorfields Eye hospital including: 1) patients attending a Uveitis clinic between 2009-2011 with a new or past history of RVO; 2) any patient who had aPL testing performed during 2010; 3) patients recruited onto the initial Ozurdex for uveitis phase III clinical trial. 34 RVO events were recorded during a two year period with an overall clinic prevalence of 1.83%. Presenting ocular features and risk factors for RVO in uveitis patients were explored. aPL testing was commonly performed on patients with RVO in an Ophthalmology setting, and the usefulness of this and its relation to RVO events were examined. Finally, follow up data for uveitis patients treated with a single Ozurdex implant were explored to determine the longer-term outcome of this treatment, and the strategies employed as and when patients relapsed, comparing these outcomes with those of the Ozurdex implant.

Стилі APA, Harvard, Vancouver, ISO та ін.

Banz, Kelly. "Calming the ocular storm : the effect of corticosteroids in inflammatory oedema." University of Western Australia. Faculty of Life and Physical Sciences, 2009. http://theses.library.uwa.edu.au/adt-WU2009.0093.

Повний текст джерела

Анотація:

The primary aim of this research is to test the therapeutic potential of certain new generation corticosteroid drugs in order to develop safe and effective treatment for eye diseases that result in oedema, or swelling. The rising incidence of diabetes and the ageing population of developed countries mean that the prevalence of uveitis, diabetic retinopathy and age related macular degeneration will rise. Often, oedema is one of the reasons for vision loss. Corticosteroids are often used to reduce inflammation. Inflammation is one of several sources of oedema. Glucocorticoids, a class of corticosteroids that have anti-inflammatory properties, are thus used to treat ocular oedema. There is an unmet need to support clinical experience of the efficacy of steroids for ocular inflammation and oedema with more substantial scientific evidence. None of the drugs under investigation, with the exceptions of dexamethasone and triamcinolone, have been used for any ocular therapeutic purpose before. This thesis investigates repurposing fludrocortisone to the ophthalmic area. 11-Desoxycorticosterone (11D) and Deoxycorticosterone (DCS), other potentially valuable mineralocorticoids, remain completely untested. Lastly, Kenacort ®, or triamcinolone acetonide (TCA), is only used off-label by ophthalmologists. Methods: In the first study, corticosteroids, and especially mineralocorticoids, were investigated for their treatment efficacy in experimental uveitis, or intraocular inflammation (using a model known as endotoxin induced uveitis). In the second study, endothelial cells from choroidal blood vessels in the back of the eye were used in vitro to study whether corticosteroids reduce paracellular (between cells) permeability. Lastly, since endophthalmitis due to frequent injections is a side effect of corticosteroid use, the pharmacokinetics of different size formulations of corticosteroids were studied in an effort to find a formula that would have a prolonged dwell time within the eye.

Стилі APA, Harvard, Vancouver, ISO та ін.

Sakkias, Filippos [Verfasser], and Stephan [Akademischer Betreuer] Thurau. "Repeat Dexamethasone implants (Ozurdex®-IVOM) for the treatment of non-infectious uveitis / Filippos Sakkias ; Betreuer: Stephan Thurau." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2020. http://d-nb.info/1204827966/34.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Greiner, Kathrin Heike. "Medical treatment of autoimmune uveitis : clinical and laboratory investigations into new therapies for non-infectious posterior segment intraocular inflammation." Thesis, University of Aberdeen, 2004. http://digitool.abdn.ac.uk/R?func=search-advanced-go&find_code1=WSN&request1=AAIU486816.

Повний текст джерела

Анотація:

The studies in this thesis were aimed at developing new treatment concepts for PSII based on the understanding of the immunological mechanisms characterised in basic research. The intensity and prognosis of inflammatory disease determine the intensity of immunosuppressive therapy. In addition to clinical features, markers of effective immunosuppression are required to guide the immunosuppressive treatment in PSII patients, especially in those patients with opaque media. A secondary aim of this thesis was, hence, the evaluation of laboratory markers, notably CD4+ T cell phenotype markers, for their prognostic value in PSII. Chapter 1 provides an introduction into the cellular and molecular mechanisms of immunological self-tolerance and autoimmunity with a special focus on T cell activation and differentiation. Then, this section discusses the current knowledge of the processes leading to autoimmune disease, e.g. autoimmune uveitis, and outlines the foundations of immunosuppressive therapy. Chapter 2 presents on overview of the clinical features, diagnosis and current treatment of strategies for PSII. Characteristics of animal models of PSII, which represent a valuable tool in developing new therapies, are discussed as well as experimental treatment concepts in PSII patients. Chapter 3 describes the experimental methods applied in this thesis. This comprises the recruitment and clinical assessment of patients as well as methods for clinical and laboratory investigations. The flow cytometry analysis of peripheral blood T cell phenotype included cell surface markers (CD69, CD62L, chemokine receptors CXCR3, CCR4, CCR5), TCRzeta and intracellular cytokines (TNFalpha, IFNgamma, IL-10). Chapter 4 presents a randomised trial on the clinical and immunological effects of cyclosporin A (CSA) and tacrolimus in 37 patients with severe PSII requiring second line immunosuppression. Nine patients (50%) on CSA and 8 patients (42%) on tacrolimus showed an improvement of logMAR visual acuity of at least 0.2 within 3 months. CSA was found to be associated with a higher incidence of side effects, e.g. increase of mean arterial pressure and serum cholesterol.

Стилі APA, Harvard, Vancouver, ISO та ін.

Koch, Philippe. "Study and treatment of intraocular inflammation by anti-inflammatory gene transfer to the retina." Doctoral thesis, Universite Libre de Bruxelles, 2011. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209901.

Повний текст джерела

Анотація:

Immunology plays an important role in many ocular disorders. With Evolution, some major organs are able to hide from the immune system. Ocular immune privilege (OIP) can be defined as the ability to raise immune tolerance against an antigen (Ag) when this Ag is placed in specific areas of the eye. Despite the presence of OIP, RPE cells transplanted to the subretinal space (SRS) encounter immune rejection. Specifically, posterior segment autoimmune uveitis (AIU) is a sight-threatening disorder affecting the working-age population. It could be defined as the alteration of OIP that allows retinal auto-antigen recognition by the immune system. Blood-retinal barrier (BRB) breakdown plays a central role in AIU, leading to invasion of leukocytes to the eye. Animal models of experimental autoimmune uveitis (EAU) play a major place in the comprehension of AIU, with correlations to human clinic. Using anti-inflammatory gene transfer to the eye with secreted proteins, different groups significantly reduced EAU development. SOCS1, being a natural intracellular down-regulator of IFNγ pathway and interacting on other cascades, appeared to be an interesting candidate.

We herein propose to study different therapeutical paradigms for intraocular inflammation using anti-inflammatory gene transfer to the retina.

Transfer of immuno-modulatory genes in RPE cells prior to their transplantation into the subretinal space could be useful to reduce immune rejection. We thus compared in vitro adeno-associated viral (AAV) gene transfer to a human immortalised RPE cell-line (ARPE-19) and primary cells (hRPE), to modify their genetic properties. We investigated 3 different serotypes and promoters in vitro, before evaluating a SOCS1 gene transfer to decrease immunogenicity of ARPE-19 cells in a xenograft rat model. We showed that AAV2 efficiently transduced at least 60% of ARPE-19 and hRPE cells, by comparison with the AAV1 and 5. In dividing ARPE-19 cells, mean-fluorescent intensity of CMV-driven gene expression was higher as compared to chicken beta-actin (CAG) and tetracycline inducible (TetON) promoters, but quickly decreased with time whereas CAG was more stable. AAV2-CAG-SOCS1 infection of ARPE-19 cells significantly decreased IFNγ-induced MHC II expression. In a last experiment, we infected in vitro ARPE-19 cells, using AAV2-CAG-SOCS1, prior to their delivery into the SRS of Lewis rats, and compared it with AAV2-CAG-eGFP-infected cells or non-infected cells. Since our preliminary results were not conclusive due to technical limitations, more extended investigations are necessary.

In another part, we developed a clinical grading system (CGS) to efficiently score EAU development in mice fundus. Particularly, we introduced the concept of active and inactive inflammation. However, some differences between CGS and histological (HGS) grading systems were pointed out to better characterise weaknesses of each method. We thus enhanced our CGS to reduce discrepancies with HGS but will need further investigations to obtain comparable grading systems.

Finally, we examined in vivo effects of a SOCS1 overexpression on EAU development, following AAV2-CAG-SOCS1 intravitreal (IVit) delivery in right eyes. We first tried two different intraocular routes of injections in this inflammatory model and showed IVit delivery to be the less traumatic. Due to important animal variabilities in EAU, SOCS1 overexpression did not lead to a significant reduction of inflammation when compared to GFP as a whole. However, our design study, allowing to compare injected versus non injected eyes, furthermore revealed IVit injection side effects with pro-inflammatory reaction due to the injection of AAV2-CAG-eGFP itself. In order to reduce the impact of inter-animal variability, we standardized the data by comparing the mean of ratios of injected over non-injected eyes (I/NI) for each animal rather than absolute values. We showed a significant reduction of the clinical and histological scores of the SOCS1 group as compared to the GFP group that was even stronger in the AAV2-targeted parts of the eyes. However, we missed a saline control to corroborate using our GFP group as a control and will need to introduce in a close future some bilateral injections to validate the use of the mean of grading ratios of I/NI in our experiments. Particularly, we showed a different pattern of MHC II positive invading cells in the ciliary body between SOCS1 treated and non-treated eyes. Further investigations are necessary to confirm and characterise SOCS1 protective mechanism in EAU.
Doctorat en Sciences médicales
info:eu-repo/semantics/nonPublished

Стилі APA, Harvard, Vancouver, ISO та ін.

Cordovil, Teresa Mota. "Uveíte recorrente equina e leptospirose : estudo de variáveis em cavalos sujeitos a vitrectomia, na região de Hannover." Master's thesis, Universidade de Lisboa. Faculdade de Medicina Veterinária, 2013. http://hdl.handle.net/10400.5/6208.

Повний текст джерела

Анотація:

Dissertação de Mestrado Integrado em Medicina Veterinária
A uveíte recorrente equina (URE) é frequentemente citada como a causa mais comum de cegueira em cavalos, apresentando prevalências entre 8 a 10% na Europa e entre 2% a 25% nos Estados Unidos. É caracterizada por episódios recorrentes de inflamação intraocular, separados por períodos de remissão, nos quais não há sinais de inflamação intraocular ativa. Evidências recentes correlacionam-na com uma forte resposta autoimune, despoletada após infeção por Leptospira. Embora a terapêutica médica anti-inflamatória seja eficaz no controlo da maioria dos casos de uveíte recorrente equina, alguns casos requerem abordagem cirúrgica, por exemplo, vitrectomia. Neste estudo foram revistos os dados referentes às vitrectomias realizadas entre Janeiro de 2012 e Janeiro de 2013, na Clínica de Equinos da Faculdade de Medicina Veterinária de Hannover. Durante a vitrectomia foram recolhidas amostras de vítreo, que foram analisadas por reação da polimerase em cadeia (PCR) e teste de aglutinação microscópica (TAM). O PCR foi positivo para 46,7% dos cavalos testados enquanto 53,3% dos cavalos apresentavam anticorpos anti-Leptospira. No total dos dois testes, 56,7% dos cavalos mostraram reação positiva para Leptospira. Foram detetados anticorpos contra o serovar Grippotyphosa em 81,3% dos cavalos positivos ao TAM. Foi encontrada uma diferença estatisticamente significativa entre a idade dos animais positivos para Leptospira e a idade dos animais negativos. A análise das lesões oculares existentes confirmou uma correlação positiva entre a gravidade das lesões e a positividade para Leptospira. Este estudo suporta a hipótese da relação entre a URE e a infeção por Leptospira no equino. Os resultados obtidos estão de acordo com os trabalhos que sugerem que a seropositividade para Leptospira está correlacionada com uma maior probabilidade do desenvolvimento de cegueira. À medida que prosseguem os estudos na procura de terapêuticas eficazes, para melhor compreensão da patogénese e dos fatores de risco da URE, a necessidade de investigação desta doença no nosso país é cada vez mais premente.
ABSTRACT - Equine Recurrent Uveitis and Leptospirosis: a study of variables in horses that underwent vitrectomy in the region of Hannover - Equine recurrent uveitis is often cited as the most common cause of blindness in horses, with prevalence of 8 to 10% in Europe and 2% to 25% in the United States. It is characterized by recurrent bouts of intraocular inflammation separated by periods of remission, in which there are no signs of active inflammation. Recent research shows it has positive correlation with strong autoimmune response, triggered by infection with Leptospira. Although anti-inflammatory medical therapy is effective in controlling most cases of equine recurrent uveitis, some cases require surgical approach, such as vitrectomy. This study reviewed the data of the horses that underwent vitrectomy between January 2012 and January 2013 in the Equine Clinic of the Faculty of Veterinary Medicine of Hannover. Vitreous samples collected during vitrectomy were analyzed by Polymerase Chain Reaction (PCR) and microscopic agglutination test (MAT). The PCR was positive in 46.7% of the horses, whereas 53.3% of the horses presented antibodies anti-Leptospira. Altogether, 56.7% of the horses showed positive reaction for Leptospira. Antibodies for serovar Grippotyphosa were detected in 81.3% of horses positive for MAT. There was a significant difference between the age of the animals positive for Leptospira and the age of the negative animals. The analysis of the ocular lesions confirmed an association between the severity of the lesions and positivity for Leptospira. This study supports the hypothesis of the link between URE and Leptospira infection in horses. The results are also in agreement with studies suggesting that Leptospira seropositive is correlated with a higher probability of developing blindness. As studies proceed in the search for effective therapies for a better understanding of the pathogenesis and the risk factors of ERU, research into this disease in our country is increasingly needed.

Стилі APA, Harvard, Vancouver, ISO та ін.

Slamang, Waheba. "A Retrospective Review of Paediatric Non-Infectious Uveitisin Cape Town: Disease Characteristics and Outcomes on Immunomodulating Treatment." Master's thesis, Faculty of Health Sciences, 2021. http://hdl.handle.net/11427/33044.

Повний текст джерела

Анотація:

Background Uveitis is a known cause of blindness in the developed world, where non-infectious diseases dominate the spectrum of underlying aetiologies. However, data from sub-Saharan Africa is lacking. Here we aim to describe the diseases associated with non-infectious uveitis and the impact of currently available treatment in this setting. Methods A retrospective observational analysis of children with non-infectious uveitis from January 2010 to December 2017, attending the tertiary paediatric rheumatology and ophthalmology referral units in Cape Town was conducted. Statistical analysis utilising STATA13 software was performed with p < 0.05 considered significant. Results Twenty-nine children were identified with a median age at first visit of 74 months (IQR 49–86 months), female to male ratio of 0.9:1, predominantly of mixed race (72.4%). Juvenile idiopathic arthritis associated uveitis (JIAU) (48.3%) was the most frequent diagnosis. All children with JIAU had chronic anterior uveitis and 3 (21.4%) presented with uveitis before arthritis. There were no differences between children with uveitis and those with arthritis only, for gender (p = 0.68) and race (p = 0.58) but significantly, children with uveitis presented at an overall younger age (p = 0.008), with antinuclear antibody positive (p < 0.001) oligo-articular JIA (p = 0.01) and older age appeared to be protective (p = 0.01 OR1.0 CI 0.6-1.7). Children with idiopathic uveitis (41.4%) were predominantly male (66.6%), of mixed race (75%), with chronic anterior uveitis (41.7%) and presented with cataracts (100%). Less commonly, sarcoidosis (6.9%) and Behcet's disease (3.5%) were diagnosed. 55.2% had complications at presentation, predominantly cataracts (87.5%). 19 children (65.5%) had inactive disease at 12 months from diagnosis and remission as assessed at the last clinical visit, was achieved in 58.6% on standard initial therapy and in 75% of those on tumour necrosis factor inhibitors. Surgery was needed in 41.4%, primarily in the idiopathic group. Visual acuity improved or was maintained on treatment. Conclusion The spectrum and characteristics of immune mediated non-infectious uveitis are comparable to that reported in developed countries. Current practice detects children with potentially sight-threatening disease and access to tumour necrosis factor inhibitors has improved outcomes in refractory cases.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ooi, Kenneth Gek-Jin. "The potential immunomodulatory effects of the statins in uveitis." Thesis, 2006. http://hdl.handle.net/2440/69455.

Повний текст джерела

Анотація:

The aim of this study was to delineate the patterns of cytokine expression which occur in various forms of immune-mediated uveitis in order to better understand their origins. Further, the study investigated the potential immunomodulatory role of the group of compounds known as the statins as adjunctive or steroid-sparing therapy in uveitis. The data recorded provides evidence for the potential of statins in the treatment of uveitis as a steroid-sparing monotherapy or as part of combination therapy.
Thesis (M.S.) -- University of Adelaide, School of Medicine, 2006

Стилі APA, Harvard, Vancouver, ISO та ін.

Hung, Tun Ywin, and 洪敦筠. "Treatment of Experimental Autoimmune Uveitis by PD-L1 Intraocular Gene Therapy." Thesis, 2012. http://ndltd.ncl.edu.tw/handle/30545904571516813818.

Повний текст джерела

Анотація:

碩士
長庚大學
醫學生物技術暨檢驗學系
100
Uveitis is a chronic inflammatory eye disease category that affects the uvea and retina and results in vision loss. The inflammation appears to be mainly associated with activation of autoreactive T cells. Many studies have indicated that PD-1 and its ligands (such as PD-L1) negatively regulate immune responses, and interaction between PD-1 and PD-L1 plays a protective role in autoimmune diseases. Therefore, here we sought to develop a PD1-targeting approach to suppress experimental autoimmune uveitis (EAU). Successful construction of rAAV delivery PD-L1 controlled by the tet-ON-inducible system (rAAV.tnPD-L1), was confirmed by in vitro infection study, in which the expression of PD-L1 was significantly increased by Dox adminiatration. EAU mice were induced with interphotoreceptor retinal binding protein (IRBP) peptide, and treated intraocularly with rAAV.tnPD-L1. The results demonstrated that rAAV.tnPD-L1 treatment significantly ameliorated the severity of EAU by reducing the retinochoroidal infiltrates of leukocytes. Percentage of Th1 and Th17 in splenic T cells were both massive reduced following rAAV.tnPD-L1 treatment. Moreover, the proinflammatory cytokines, including IFN-γ and IL-17, and proliferation of IRBP-specific T cells derived from the treated group were both reduced. Our data suggest the administration of PD-L1, attenuating EAU intraocular inflammation mainly through suppressing the proinflammatory cytokine produced by IRBP-specific T cells, may be a promising therapeutic strategy in uveitis.

Стилі APA, Harvard, Vancouver, ISO та ін.

Fischer, Britta Maria. "Intravitreal injection of low-dose Gentamicin: an alternative method of management for equine recurrent uveitis." 2020. https://ul.qucosa.de/id/qucosa%3A72762.

Повний текст джерела

Анотація:

Die Technik der intravitrealen Gentamicin Injektion darzulegen, die Auswirkungen dieser auf die klinischen Symptome von Uveitiden, sowie die möglichen unmittelbaren Komplikationen (innerhalb von 24 Stunden) und längerfristigen Komplikationen (30 bis 780 Tage) die mit dieser Technik verbunden sein können, zu beschreiben. Zusätzlich wurde der okuläre und systemische Leptospiren- Status ermittelt und der Einfluss dieser auf das Behandlungsergebnis untersucht.:Table of Contents 1 INTRODUCTION 1 2 LITERATURE OVERVIEW 2 2.1 Etiology and pathogenesis 2 2.1.1 Proposed etiologies 2 2.1.2 ERU: an immune mediated disease 3 2.2 Leptospirosis and ERU 4 2.2.1 Genetic predisposition for ERU 6 2.3 Definition of ERU 7 2.3.1 Classification and syndromes 7 2.3.2 Clinical symptoms 8 2.4 Diagnostic testing for ERU (Leptospira) 8 2.4.1 Sample collection (aqueous humor, vitreous humor, serum) 8 2.4.2 Methodology 9 2.4.2.1 Microagglutination test (MAT) 9 2.4.2.2 Polymerase chain reaction (PCR) 10 2.4.2.3 Cultures 10 2.5 Treatment of ERU 10 2.5.1 Medical management 10 2.5.2 Intravitreal and suprachoroidal injections 11 2.5.2.1 Intravitreal rapamycin injections 11 2.5.2.2 Intravitreal triamcinolone injections 11 2.5.2.3 Suprachoroidal triamcinolone injections 12 2.5.2.4 Low-dose intravitreal gentamicin injections 12 2.5.3 Surgical procedures 13 2.5.3.1 Suprachoroidal cyclosporine implants 13 2.5.3.2 Pars plana vitrectomy 14 3 PUBLICATIONS 16 3.1 Intravitreal injection of low-dose gentamicin for the treatment of recurrent or persistent uveitis in horses: Preliminary results 16 3.2 Medical and Surgical Management of Equine Recurrent Uveitis 29 4 DISCUSSION 47 5 ZUSAMMENFASSUNG 51 6 SUMMARY 52 7 REFERENCES 53
To describe the intravitreal gentamicin injection technique, report the effects of the injection on the clinical signs of uveitis and to describe the associated peri-injection (within 24 hours) and post-injection complications (30 to 780 days). Additionally, evaluation of the systemic and ocular Leptospira status and its effects on the treatment outcome was performed.:Table of Contents 1 INTRODUCTION 1 2 LITERATURE OVERVIEW 2 2.1 Etiology and pathogenesis 2 2.1.1 Proposed etiologies 2 2.1.2 ERU: an immune mediated disease 3 2.2 Leptospirosis and ERU 4 2.2.1 Genetic predisposition for ERU 6 2.3 Definition of ERU 7 2.3.1 Classification and syndromes 7 2.3.2 Clinical symptoms 8 2.4 Diagnostic testing for ERU (Leptospira) 8 2.4.1 Sample collection (aqueous humor, vitreous humor, serum) 8 2.4.2 Methodology 9 2.4.2.1 Microagglutination test (MAT) 9 2.4.2.2 Polymerase chain reaction (PCR) 10 2.4.2.3 Cultures 10 2.5 Treatment of ERU 10 2.5.1 Medical management 10 2.5.2 Intravitreal and suprachoroidal injections 11 2.5.2.1 Intravitreal rapamycin injections 11 2.5.2.2 Intravitreal triamcinolone injections 11 2.5.2.3 Suprachoroidal triamcinolone injections 12 2.5.2.4 Low-dose intravitreal gentamicin injections 12 2.5.3 Surgical procedures 13 2.5.3.1 Suprachoroidal cyclosporine implants 13 2.5.3.2 Pars plana vitrectomy 14 3 PUBLICATIONS 16 3.1 Intravitreal injection of low-dose gentamicin for the treatment of recurrent or persistent uveitis in horses: Preliminary results 16 3.2 Medical and Surgical Management of Equine Recurrent Uveitis 29 4 DISCUSSION 47 5 ZUSAMMENFASSUNG 51 6 SUMMARY 52 7 REFERENCES 53

Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Uveitis treatment"

Lin, Phoebe, and Eric Suhler, eds. Treatment of Non-infectious Uveitis. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-22827-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kanski, Jack J. Uveitis: A colour manual of diagnosis and treatment. London: Butterworths, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

1934-, Nozik Robert A., ed. Surgical treatment of ocular inflammatory disease. Philadelphia: Lippincott, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

New treatments in non-infectious uveitis. Basel: Karger, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Diagnosis and Treatment of Uveitis. Saunders, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Diagnosis and Treatment of Uveitis. Jaypee Brothers Medical Publishers (P) Ltd., 2013. http://dx.doi.org/10.5005/jp/books/11822.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lin, Phoebe, and Eric Suhler. Treatment of Non-infectious Uveitis. Springer, 2019.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Diagnosis And Treatment Of Uveitis. Jaypee Brothers Medical Publishers, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yang, Peizeng. Atlas of Uveitis: Diagnosis and Treatment. Springer Singapore Pte. Limited, 2020.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yang, Peizeng. Atlas of Uveitis: Diagnosis and Treatment. Springer Singapore Pte. Limited, 2021.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Uveitis treatment"

BenEzra, D., E. Cohen, and G. Maftzir. "Prediction of Treatment Outcome in Uveitis." In Uveitis Update, 160–65. Basel: KARGER, 1999. http://dx.doi.org/10.1159/000060763.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Miserocchi, Elisabetta, Umberto De Benedetto, and Giulio Modorati. "Treatment of Intermediate Uveitis." In Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders, 135–59. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-54350-0_9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

BenEzra, D., R. B. Nussenblatt, and P. Timonen. "Treatment of Endogenous Uveitis." In Optimal Use of Sandimmun in Endogenous Uveitis, 6–8. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-83368-7_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Testi, Ilaria, Andres Rousselot, Rupesh Agrawal, and Carlos Pavesio. "Treatment of Uveitic Macular Edema." In Complications in Uveitis, 205–16. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28392-6_15.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Francis, Andrew W., and Andrea D. Birnbaum. "Topical Therapy in Uveitis." In Treatment of Non-infectious Uveitis, 5–13. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-22827-9_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Neri, Piergiorgio. "Treatment of Inflammatory Choroidal Neovascular Membranes." In Complications in Uveitis, 159–68. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28392-6_11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Knickelbein, Jared E., Karen R. Armbrust, Meredith Kim, H. Nida Sen, and Robert B. Nussenblatt. "Pharmacologic Treatment of Noninfectious Uveitis." In Handbook of Experimental Pharmacology, 231–68. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/164_2016_21.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wu, Xia Ni, and Lyndell Lim. "Local Drug Delivery for Noninfectious Uveitis." In Treatment of Non-infectious Uveitis, 157–77. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-22827-9_13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Banda, Himanshu K., and Steven Yeh. "Special Considerations: Treatment of Pediatric Uveitis." In Treatment of Non-infectious Uveitis, 189–200. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-22827-9_15.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Lin, Phoebe, and Eric Suhler. "Introduction." In Treatment of Non-infectious Uveitis, 1–3. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-22827-9_1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Uveitis treatment"

Konovalova, N. V., and N. I. Khramenko. "To the Treatment of Anterior Uveitis." In 2019 IEEE 8th International Conference on Advanced Optoelectronics and Lasers (CAOL). IEEE, 2019. http://dx.doi.org/10.1109/caol46282.2019.9019547.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Guimarães Nolasco Farias, Lucas, Bruno Batista da Cunha Filho, Amanda Bernardes, Sofia Silveira de Castro Mirand, Paulo Guilherme de Oliveira Barbalho Junior, Elaine de Azevedo, and Rina Dalva Neubarth Giorgi. "Acute anterior uveitis after zoledronic acid infusion for osteoporosis treatment." In SBR 2021 Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2021.1937.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zheng, W., J. Shi, C. Zhao, J. Liu, J. Zhou, F. Gao та M. Zhang. "AB0710 Interferon Α2a for the treatment of refractory behÇet’s disease uveitis". У Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3453.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Banares, A., E. Pato, L. Abasolo, P. Macarron, C. Hernandez, JA Jover, and B. Fernandez. "THU0235 Treatment of refractory posterior uveitis with anti-tnf-alfa (infliximab)." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.767.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Silva, Vitória Pimentel da, Lucas Immich Gonçalves, Giordani Rodrigues dos Passos, Maísa Kappel, Mayumi Charão, and Jefferson Becker. "Vogt-Koyanagi-Harada Syndrome: case report." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.637.

Повний текст джерела

Анотація:

Context: Red eye complaints are common in medical practice. Trauma, infection and autoimmune disorders are possible causes. It is essential to diagnose early to avoid sequelae. Case report: Female, 58 years old, 30 days of progression of bilateral frontal and retro-orbital headache associated with red eye and decreased visual acuity in both eyes, otalgia and tinnitus in the left ear. No trauma history. She started treatment in another hospital with acyclovir for suspected viral meningitis and was referred for evaluation after 10 days due to the lack of improvement. In our evaluation, the patient had severely impaired visual acuity (counted fingers in the RE and 20/400 in the LE), with uveitis, papilloedema and bilateral serous retinal detachment. Lumbar puncture showed aseptic meningitis (940 leukocytes with 100% lymphocytes, 66 mg/dL proteins, normal glucose and negative evaluation for CSF infections). Laboratory tests showed an increase in inflammatory markers (VSG 121) and positive anti-TPO, with other negative autoantibodies. Brain MRI with subacute retinal detachment, without intracranial lesions. Audiometry with mild to moderate bilateral sensorineural hearing loss. The patient was treated with IV methylprednisolone for 5 days with partial symptom improvement. Conclusion: Among the bilateral uveitis causes, it is crucial to remember Vogt-Koyanagi-Harada Syndrome (VKH), which occurs through bilateral uveitis, sometimes accompanied by retinal detachment, in association with hypochromic skin lesions, sensorineural hearing loss, headache and aseptic meningitis2 . VKH results from an autoimmune lesion in the melanocytes3 . Treatment should be done with topical corticosteroid, associated with cycloplegics and systemic corticosteroid therapy with long-term immunosuppression2.

Стилі APA, Harvard, Vancouver, ISO та ін.

Uriarte, M., C. Martín, J. Gonzalez, R. García de Vicuña, E. Pato, M. Gorroño, Á. M. Aparicio, and M. Cordero. "SAT0595 Analysis of recurrences after suspension of immunosuppressive treatment in non-infectious uveitis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5105.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

El-Shabrawi, Y., and J. Hermann. "THU0230 Anti-tnfa therapy with infliximab in the treatment of hla b27 associated acute anterior uveitis." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.762.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Martín-Varillas, J. L., V. Calvo-Río, E. Beltrán, J. Sánchez, M. Mesquida, A. Adán, M. V. Hernández, et al. "AB0669 Maintenance treatment with adalimumab in refractory uveitis due to behÇet’s disease: optimised vs non-optimised group." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3963.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Gόmez-Gόmez, A., E. Loza, MP Rosario, L. Carmona, G. Espinosa, JM García Ruíz de Morales, JM Herrera, S. Muñoz-Fernández, and M. Cordero. "THU0549 Systemic treatment for acute anterior uveitis (synthetic and biologic disease-modifying antirheumatic drugs): a systematic review." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2626.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

McDonald, Joseph, Virginia Utz, Theresa Hennard, Najima Mwase, Jessi Lipscomb, Amy Cassedy, and Sheila Angeles-Han. "AB1019 THE EFFECT OF TREATMENT REGIMEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN CHILDREN WITH UVEITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.5913.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Uveitis treatment"

Li, Biao, Haoran Li, Li Zhang, and Yanlin Zheng. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0116.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Li, Biao, Haoran Li, Li Zhang та Yanlin Zheng. Efﬁcacy and safety of adalimumab in the treatment of Juvenile Idiopathic Arthritis-Associated Uveitis: a meta-analysis and systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, листопад 2020. http://dx.doi.org/10.37766/inplasy2020.11.0002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!